Ark Biopharmaceutical Secures China Marketing Approval for Aizhida, Expanding Treatment Options for ADHD
World Economic Magazine
January 13, 2026
ArkBio has received NMPA approval for Aizhida, a new ADHD treatment for patients aged six and above, marking a key advancement in China’s neuropsychiatric drug landscape.
